MWNA
SGMO

Marshall Wace North America’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Marshall Wace North America’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-83,826
Closed -$751K – 1447
2020
Q2 		$751K Sell
83,826
-182,858
-69% -$1.7M 0.01% 842
2020
Q1 		$1.7M Buy
266,684
+235,338
+751% +$1.75M 0.01% 517
2019
Q4 		$263K Sell
31,346
-1,000,468
-97% -$9.2M ﹤0.01% 920
2019
Q3 		$9.34M Buy
+1,031,814
New +$11.6M 0.05% 270
2019
Q1 		– Sell
-22,086
Closed -$254K – 1870
2018
Q4 		$254K Buy
+22,086
New +$274K ﹤0.01% 914
2013
Q3 		– Sell
-11,701
Closed -$91K – 696
2013
Q2 		$91K Buy
+11,701
New +$102K 0.01% 413

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's SGMO Position: Q3 2020 in Review

Marshall Wace North America sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2020, closing a stake of 83,826 shares — an estimated $751K sold.

Marshall Wace North America first reported a position in SGMO in Q2 2013 and held it in 6 quarters. The position peaked at $9.34M in Q3 2019. 210 funds tracked by Wall St. Rank hold SGMO as of Q3 2020.

  • Marshall Wace North America reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 83,826 SANGAMO THERAPEUTICS INC shares in Q3 2020, an estimated $751K.
  • Marshall Wace North America first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 6 quarters.
  • Marshall Wace North America's SANGAMO THERAPEUTICS INC position peaked at $9.34M in Q3 2019.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.